Back HIV/AIDS HIV/AIDS Topics HIV Prevention

IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa

One of the first studies to explore the acceptability, safety, and use of pre-exposure prophylaxis (PrEP) in adolescents in an African context has found that PrEP was safe and tolerable, although PrEP usage and adherence did tail off during the 12 months of the program.

alt

Read more:

IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year

A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, now running, is only the eighth human vaccine efficacy trial ever run in the history of the HIV epidemic, and the first since 2009.

alt

Read more:

IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention

A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.

alt

Read more:

IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners

A study of 343 gay couples, where one partner had HIV and the other did not, has not found a single case of HIV transmission in 16,889 acts of condomless anal sex, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.

alt

Read more:

IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland

New HIV infections have been cut in half in Swaziland since 2011, at the same time as the proportion of people on antiretroviral treatment with fully suppressed viral load has doubled, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris. It is the first direct evidence that expanding HIV treatment results in fewer HIV infections in a country with a major epidemic, researchers said.

alt

Read more: